DekaBank Deutsche Girozentrale Decreases Stock Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

DekaBank Deutsche Girozentrale lowered its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 84.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,875 shares of the medical instruments supplier’s stock after selling 25,878 shares during the period. DekaBank Deutsche Girozentrale’s holdings in OraSure Technologies were worth $40,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in OraSure Technologies by 1.2% during the third quarter. Vanguard Group Inc. now owns 5,396,285 shares of the medical instruments supplier’s stock worth $32,000,000 after buying an additional 64,367 shares in the last quarter. Earnest Partners LLC raised its position in OraSure Technologies by 5.2% during the first quarter. Earnest Partners LLC now owns 5,123,334 shares of the medical instruments supplier’s stock worth $34,736,000 after acquiring an additional 251,955 shares during the last quarter. State Street Corp raised its position in OraSure Technologies by 1.9% during the second quarter. State Street Corp now owns 3,440,307 shares of the medical instruments supplier’s stock worth $9,323,000 after acquiring an additional 63,392 shares during the last quarter. Dimensional Fund Advisors LP raised its position in OraSure Technologies by 6.9% during the first quarter. Dimensional Fund Advisors LP now owns 3,156,930 shares of the medical instruments supplier’s stock worth $21,405,000 after acquiring an additional 205,126 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its position in OraSure Technologies by 8.7% during the third quarter. Neuberger Berman Group LLC now owns 2,953,375 shares of the medical instruments supplier’s stock worth $11,214,000 after acquiring an additional 236,827 shares during the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.

OraSure Technologies Trading Up 0.6 %

Shares of OSUR opened at $5.25 on Thursday. The company has a 50-day moving average of $6.56 and a two-hundred day moving average of $6.82. The stock has a market cap of $401.68 million, a P/E ratio of 7.29 and a beta of 0.15. OraSure Technologies, Inc. has a 12-month low of $4.38 and a 12-month high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.09. The business had revenue of $75.88 million during the quarter, compared to analyst estimates of $74.13 million. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The company’s revenue was down 38.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.21 earnings per share. As a group, analysts forecast that OraSure Technologies, Inc. will post -0.11 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Evercore ISI cut their target price on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a research report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $6.38.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.